PT - JOURNAL ARTICLE AU - Nicholas P. Giangreco AU - Nicholas P. Tatonetti TI - A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development AID - 10.1101/2021.07.15.21260602 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.15.21260602 4099 - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260602.short 4100 - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260602.full AB - Adverse drugs effects (ADEs) in children are common and may result in disability and death. However, current pediatric drug safety methods have not gone beyond event surveillance to identify and evaluate potential biological mechanisms. Children undergo an evolutionarily conserved and physiologically dynamic process of growth and maturation that can alter pharmacokinetics and pharmacodynamics. Our hypothesis is that temporal patterns of drug event reporting are reflective of dynamic mechanisms from child growth and development. We generated a database of 460,837 pediatric ADEs using generalized additive models (GAMs) that we have previously shown identify dynamic risk estimates of adverse drug events1. We identified 19,438 significant drug-event risks where drug risks corresponded with physiological development throughout childhood. Our results identified known pediatric drug effects and risk dynamics across child development that were not known previously. For example, we identified significant risk dynamics of montelukast-induced psychiatric disorders, including enriched risk (Odds Ratio 8.77 [2.51, 46.94]) within the second year of life. We developed a data-driven time- series clustering approach resulting in up to 95.2% precision and 97.8% sensitivity for categorizing risk dynamics across development stages for all ADEs including known but previously development-agnostic pediatric drug effects. We found that our real-world evidence may contain biologically-relevant underpinnings as well, where risk dynamics of CYP enzyme substrates were dependent on the enzyme’s expression across childhood. We curated this database for the research community to enable, for the first time, evaluation of real-world hypotheses of adverse drug effects across child growth and development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNPG and NPT are funded by R35GM131905Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://github.com/ngiangre/pediatric_ade_database_study